AccScience Publishing / GTM / Volume 2 / Issue 3 / DOI: 10.36922/gtm.1455

Immediate onset signatures of autoimmune diseases after vaccination

Darrell O. Ricke1*
Show Less
1 Department of Research, Molecular BioInsights, Winchester, MA, 01890, USA
Global Translational Medicine 2023, 2(3), 1455
Submitted: 8 August 2023 | Accepted: 20 September 2023 | Published: 29 September 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Severe adverse events, including autoimmune diseases, have been noted in some individuals following vaccination. It is still unknown whether a subset of these autoimmune disease adverse events (ADAE) is triggered by the immunization and is not background chance occurrences. Only a small fraction of adverse events experienced by vaccinees has been reported to the Vaccine Adverse Event Reporting System (VAERS) database. In this study, ADAEs within VAERS are examined. The frequency of autoimmune disease adverse reactions reported immediately following vaccination was compared to the background population adverse event frequency. The frequency of immediate-onset autoimmune diseases, extracted from VAERS, arisen after vaccination was found to exceed the expected background occurrences. Vaccinees who receive a second COVID-19 mRNA vaccination dose 3 weeks after the first dose appear to experience an increased number of ADAE. Furthermore, human papillomavirus (HPV), hepatitis A, and hepatitis B vaccines exhibit distinctive patterns of associations with autoimmune diseases. The potential role of vaccine aluminum adjuvant, included in these vaccines, cannot be ruled out as contributing to ADAE. VAERS data illustrate immediate onset correlations for multiple autoimmune diseases across various vaccines. Autoimmune diseases immediate temporal onset associations that occur following COVID-19 mRNA and adenoviral vaccinations are predicted to occur with similar frequencies for all mRNA and adenoviral vaccines and therapeutics. Taken together, removal of aluminum adjuvants from HPV, hepatitis A, and hepatitis B vaccines, among others, should be considered in the effort to reduce the occurrence of immediate-onset autoimmune diseases.

Autoimmune diseases
COVID-19 vaccines
Human papillomavirus vaccines
Hepatitis vaccines
Aluminum adjuvant
  1. VAERS, 2023, Vaccine Adverse Event Reporting System. U.S. Department of Health and Human Services. Available from: [Last accessed on 2023 Aug 08].


  1. Vadalà M, Poddighe D, Laurino C, et al., 2017, Vaccination and autoimmune diseases: Is prevention of adverse health effects on the horizon? EPMA J, 8: 295–311.


  1. Guimarães LE, Baker B, Perricone C, et al., 2015, Vaccines, adjuvants and autoimmunity. Pharmacol Res, 100: 190–209.


  1. Seida I, Seida R, Elsalti A, et al., 2023, Vaccines and autoimmunity-from side effects to ASIA syndrome. Medicina (Kaunas), 59: 364.


  1. Babazadeh A, Afshar ZM, Javanian M, et al., 2019, Influenza vaccination and Guillain-Barré syndrome: Reality or fear. J Transl Int Med, 7: 137–142.


  1. Sencer D, Millar JD, 2006, Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis J, 12: 29–33.


  1. Vellozzi C, Iqbal S, Broder K, 2014, Guillain-Barré syndrome, influenza, and influenza vaccination: The epidemiologic evidence. Clin Infect Dis, 58: 1149–1155.


  1. Ahmed SS, Schur PH, MacDonald NE, et al., 2014, Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun, 50: 1–11.


  1. David P, Shoenfeld Y, 2020, ITP following vaccination. Int J Infect Dis, 99: 243–244.


  1. Black C, Kaye JA, Jick H, 2003, MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol, 55: 107–111.


  1. Jin CQ, Dong HX, Sun ZX, et al., 2013, Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine (OPV). Hum Vaccin Immunother, 9: 1739–1740.


  1. Chen Y, Xu Z, Wang P, et al., 2022, New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology, 165: 386–401.


  1. May Lee M, Bertolani M, Pierobon E, et al., 2022, Alopecia areata following COVID-19 vaccination: Vaccine-induced autoimmunity? Int J Dermatol, 61: 634–635.


  1. Rossini A, Cassibba S, Perticone F, et al., 2023, Increased prevalence of autoimmune thyroid disease after COVID- 19: A single-center, prospective study. Front Endocrinol (Lausanne), 14: 1126683.


  1. Guo M, Liu X, Chen X, et al., 2023, Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun Rev, 22: 103340.


  1. Ishay Y, Kenig A, Tsemach-Toren T, et al., 2021, Autoimmune phenomena following SARS-CoV-2 vaccination. Int Immunopharmacol, 99: 107970.


  1. Ruggeri RM, Giovanellla L, Campennì A, 2022, SARS-CoV-2 vaccine may trigger thyroid autoimmunity: Real-life experience and review of the literature. J Endocrinol Invest, 45: 2283–2289.


  1. Pujol A, Gómez LA, Gallegos C, et al., 2022, Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: From Graves’ disease to silent thyroiditis. J Endocrinol Invest, 45: 875–882.


  1. Elrashdy F, Tambuwala MM, Hassan SS, et al., 2021, Autoimmunity roots of the thrombotic events after COVID- 19 vaccination. Autoimmun Rev, 20: 102941.


  1. Rodríguez Y, Rojas M, Beltrán S, et al., 2022, Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun, 132: 102898.


  1. Kaulen LD, Doubrovinskaia S, Mooshage C, et al., 2022, Neurological autoimmune diseases following vaccinations against SARS-CoV-2: A case series. Eur J Neurol, 29: 555–563.


  1. Shaw CA, Tomljenovic L, 2013, Aluminum in the central nervous system (CNS): Toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res, 56: 304–316.


  1. Watad A, David P, Brown S, et al., 2017, Autoimmune/ inflammatory syndrome induced by adjuvants and thyroid autoimmunity. Front Endocrinol (Lausanne), 7: 150.


  1. Willame C, Dodd C, van der Aa L, et al., 2021, Incidence rates of autoimmune diseases in European healthcare databases: A contribution of the ADVANCE project. Drug Saf, 44: 383–395.


  1. Willame C, Rosillon D, Zima J, et al., 2016, Risk of new onset autoimmune disease in 9-to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother, 12: 2862–2871.


  1. Angelo MG, David MP, Zima J, et al., 2014, Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf, 23: 466–479.


  1. Ricke DO, 2022, Etiology model for many vaccination adverse reactions, including SARS-CoV-2 spike vaccines. AIMS Allergy Immunol, 6: 200–215.


  1. Ricke DO, 2023, VAERS-tools. Available from: https://github. com/doricke/vaers-tools [Last accessed on 2023 Aug 08].


  1. Michet CJ, Matteson EL, 2008, Polymyalgia rheumatica. BMJ, 336: 765–769.


  1. Gherardi RK, Authier FJ, 2012, Macrophagic myofasciitis: Characterization and pathophysiology. Lupus, 21: 184–189.


  1. Tomljenovic L, Colafrancesco S, Perricone C, et al., 2014, Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “autoimmune/auto-inflammatory syndrome induced by adjuvants”: Case report and literature review. J Investig Med High Impact Case Rep, 2(1).


  1. Anaya JM, Reyes B, Perdomo-Arciniegas AM, et al., 2015, Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: A call for personalised medicine. Clin Exp Rheumatol, 33: 545–548.


  1. Chung JY, Lee SJ, Shin BS, et al., 2018, Myasthenia gravis following human papillomavirus vaccination: A case report. BMC Neurol, 18: 222.


  1. Kinoshita T, Abe RT, Hineno A, et al., 2014, Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med, 53: 2185–2200.


  1. Kong K, Ding X, Ni Y, 2022, Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: A case report. Hum Vaccin Immunother, 18: 1–4.


  1. Gomes SM, Glover M, Malone M, et al., 2013, Vasculitis following HPV immunization. Rheumatology (Oxford), 52: 581–582.


  1. Poddighe D, Castelli L, Marseglia GL, et al., 2014, A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: Might it be an autoimmune/ inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? Immunol Res, 60: 236–246.


  1. Mehlsen J, Brinth L, Pors K, et al., 2022, Autoimmunity in patients reporting long-term complications after exposure to human papilloma virus vaccination. J Autoimmun, 133: 102921.


  1. CDC, 2023, Vaccine Excipient Summary. Available from: https:// excipient-table-2.pdf [Last accessed on 2023 Aug 08].


  1. Geier DA, Geier MR, 2005, A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity, 38: 295–301.


  1. Gross K, Combe C, Krüger K, et al., 1995, Arthritis after hepatitis B vaccination. Report of three cases. Scand J Rheumatol, 24: 50–52.


  1. Rahimi SS, Ostrov BE, Lopez-Pena M, 2021, Inflammatory arthritis following hepatitis B vaccination in an infant. Case Rep Rheumatol, 2021: 5598217.


  1. Wise RP, Kiminyo KP, Salive ME, 1997, Hair loss after routine immunizations. JAMA, 278: 1176–1178.


  1. Erguven M, Guven S, Akyuz U, et al., 2009, Optic neuritis following hepatitis B vaccination in a 9-year-old girl. J Chin Med Assoc, 72: 594–597.


  1. Sudarshan S, Huang EH, Lim PL, et al., 2012, A case of post-vaccination optic neuritis: Coincidence or causative? Eye (Lond), 26: 1498.


  1. Cockwell P, Allen MB, Page R, 1990, Vasculitis related to hepatitis B vaccine. BMJ, 301: 1281.


  1. Awad MH, El-Hawary A, Sawah G, et al., 2021, Pan-vasculitis and fulminant hepatitis following routine vaccination at the age of 4 months. Clin Exp Vaccine Res, 10: 78–80.


  1. Finielz P, Lam-Kam-Sang LF, Guiserix J, 1998, Systemic lupus erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine. Nephrol Dial Transplant, 13: 2420–2421.


  1. Blumenthal D, Prais D, Bron-Harlev E, et al., 2004, Possible association of Guillain-Barré syndrome and hepatitis A vaccination. Pediatr Infect Dis J, 23: 586–588.


  1. Tourbah A, Gout O, Liblau R, et al., 1999, Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS? Neurology, 53: 396–401.


  1. Pordeus V, Szyper-Kravitz M, Levy RA, et al., 2008, Infections and autoimmunity: A panorama. Clin Rev Allergy Immunol, 34: 283–299.


  1. Ricke DO, 2021, Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol, 12: 640093.


  1. Ricke DO, 2021, Etiology scenarios for multisystem inflammatory syndrome in children and adults associated with SARS-CoV-2. J Integr Pediatr Healthc, 3: 1–5.


  1. Liang Y, Meng FY, Pan HF, et al., 2015, A literature review on the patients with autoimmune diseases following vaccination against infections. Hum Vaccin Immunother, 11: 2274–2280.


  1. Frasca L, Ocone G, Palazzo R, 2023, Safety of COVID-19 vaccines in patients with autoimmune diseases, in patients with cardiac issues, and in the healthy population. Pathogens, 12: 223.


  1. Ferri C, Ursini F, Gragnani L, et al., 2021, Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. J Autoimmun, 125: 102744.


  1. Efe C, Taşçılar K, Gerussi A, et al., 2022, SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. J Autoimmun, 132: 102906.
Conflict of interest
The author declares no competing interests.
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Published by AccScience Publishing